Dementia is a clinical and public health issue of growing importance as life expectancy increases across the planet. Despite advances in both genetic research and clinical management strategies, neither cure nor primary prevention is currently feasible. However, screening for dementia is critical for secondary prevention, i.e., early diagnosis and treatment as well as disability limitation and prevention of complications. Screening is also important for community surveillance and the planning of health and human services. The most appropriate screening approach for a particular clinical or research setting should be selected on the basis of the purpose of screening in that setting. Ideally, all elderly individuals, as well as younger persons with known risk factors, should be routinely screened for dementia. Availability of staff resources, including time and skills, should also be taken into account. Objective cognitive testing appears to be the most logical approach to screening for dementia. However, potential confounding variables and psychometric properties of the instruments should be considered. Ancillary measures such as functional disability scales, self-reported cognitive functioning, and informants' perceptions may usefully supplement (or supplant) cognitive testing in certain populations. The limitations of screening should be recognized.
Download full-text PDF |
Source |
---|---|
http://dx.doi.org/10.1159/000109697 | DOI Listing |
Can Assoc Radiol J
January 2025
North York General Hospital, Toronto, ON, Canada.
The Canadian Association of Radiologists (CAR) Central Nervous System Expert Panel is made up of physicians from the disciplines of radiology, emergency medicine, neurosurgery, and neurology, a patient advisor, and an epidemiologist/guideline methodologist. After developing a list of 24 clinical/diagnostic scenarios, a rapid scoping review was undertaken to identify systematically produced referral guidelines that provide recommendations for one or more of these clinical/diagnostic scenarios. Recommendations from 55 guidelines and contextualization criteria in the Grading of Recommendations, Assessment, Development, and Evaluations (GRADE) for guidelines framework were used to develop 51 recommendation statements across the 24 scenarios.
View Article and Find Full Text PDFStroke
January 2025
Neurology, Feil Family Brain and Mind Research Institute, Weill Cornell Medicine, UNITED STATES.
To study the risk of incident dementia after a non-traumatic intracranial hemorrhage in a diverse US population, and evaluate if this risk is different for the subtypes of intracranial hemorrhage. We performed a retrospective cohort study using both inpatient and outpatient claims data on Medicare beneficiaries between January 1, 2008 and December 31, 2018. The exposure was a new diagnosis of non-traumatic intracranial hemorrhage, defined as a composite of intracerebral hemorrhage (ICH), subarachnoid hemorrhage (SAH), and subdural hemorrhage (SDH).
View Article and Find Full Text PDFFront Neurol
January 2025
14th European Reference Network in Neuromuscular Disorders (EURO-NMD), Scientific Laboratory of Molecular Genetics, Riga Stradins University, Riga, Latvia.
Background: Charcot-Marie-Tooth disease (CMT), a slowly advancing hereditary nerve disorder, presents a significant challenge in the medical field. Effective drugs for treatment are lacking, and we struggle to find sensitive markers to track the disease's severity and progression. In this study, our objective was to investigate the levels of neurofilament light chain (NfL), glial fibrillary acid protein (GFAP), fibroblast growth factor 21 (FGF-21) and growth differentiation factor 15 (GDF-15) in individuals with CMT and to compare them to a control group.
View Article and Find Full Text PDFFront Aging Neurosci
January 2025
Experimental and Computational Biochemistry, Department of Nutrition and Biochemistry, Faculty of Sciences, Pontificia Universidad Javeriana, Bogotá, Colombia.
Mild cognitive impairment (MCI) is characterized by a decline in cognitive functioning without significant interference in daily activities. Its high heterogeneity and elevated conversion rate to dementia pose challenges for accurate diagnosis and monitoring, highlighting the urgent need to identify methodologies focused on the early detection and intervention of MCI. Due to their biological characteristics, microRNAs (miRNAs) are potential candidates as non-invasive molecular markers for the identification and assessment of MCI progression.
View Article and Find Full Text PDFJMIR Med Inform
January 2025
Fundación INTRAS, Valladolid, Spain.
Background: This review explores the potential of virtual reality (VR) and artificial intelligence (AI) to identify preclinical cognitive markers of Alzheimer disease (AD). By synthesizing recent studies, it aims to advance early diagnostic methods to detect AD before significant symptoms occur.
Objective: Research emphasizes the significance of early detection in AD during the preclinical phase, which does not involve cognitive impairment but nevertheless requires reliable biomarkers.
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!